Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karo Bio and Zydus Cadila have decided to extend their research pact for discovering and developing new anti-inflammatory drug compounds which affect glucocorticoid receptors in a selective manner.
Subscribe to our email newsletter
Glucocorticoids are used to treat many different inflammatory conditions such as rheumatoid arthritis, inflammatory bowels disease, psoriasis and asthma.
The goal of the extended agreement is to design new selective glucocorticoids to treat inflammatory diseases.
Karo Bio CEO Fredrik Lindgren said to date the collaboration has generated several novel compounds that may have potential as drug candidates.
"We have decided to extend our collaboration for another year to allow us to continue to combine the strengths of Karo Bio and Zydus Cadila to jointly study these further," Lindgren said.